MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma

Background: Hepatic resection, radiofrequency ablation (RF), and liver transplantation (LT) represent the only available curative treatments for early stage hepatocellular carcinoma (HCC). Various studies showed that the 5-year overall survival (OS) rate reaches ∼70% after resection and ∼60% after R...

Descripción completa

Detalles Bibliográficos
Autores principales: Grisetti, Luca, Võ, Niệm Văn Thành, Nguyễn, Như Nhật Quỳnh, Crocè, Lory Saveria, Visintin, Alessia, Tiribelli, Claudio, Pascut, Devis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Cellular and Molecular Pathogenesis of Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772976/
https://www.ncbi.nlm.nih.gov/pubmed/36537076
http://dx.doi.org/10.1177/15330338221132924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772976/
https://www.ncbi.nlm.nih.gov/pubmed/36537076
http://dx.doi.org/10.1177/15330338221132924

Ejemplares similares